AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q3 FY25 results · Oct–Dec 2024
AstraZeneca Pharma India reported revenue from operations of ₹440.29 crore (up 44.0% from Q3 FY24) and net profit of ₹30.85 crore (up 95.2% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a standalone basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 440.29 | 305.79 | +44.0% | 408.00 | +7.9% |
| Other income | 7.98 | 9.66 | −17.4% | 8.15 | −2.1% |
| Total income | 448.27 | 315.45 | +42.1% | 416.15 | +7.7% |
| Profit before tax | 42.02 | 20.40 | +106.0% | 51.03 | −17.7% |
| Net profit for the period | 30.85 | 15.80 | +95.2% | 38.43 | −19.7% |
| EPS, basic (₹) | 12.34 | 6.32 | +95.3% | 15.37 | −19.7% |
| Net margin (%) | 7.0 | 5.2 | 9.4 |
Standalone
- Filed with BSE
- 11 Feb 2025, 19:42 IST
- Board meeting
- 11 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE